Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes three candidates currently in clinical development: PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor, and a preclinical oral candidate targeting SMARCA2.
View Top Employees from Prelude TherapeuticsWebsite | http://www.preludetx.com/ |
Revenue | $40 million |
Funding | $268 million |
Employees | 146 (146 on RocketReach) |
Founded | 2016 |
Address | 175 Innovation Boulevard, Wilmington, Delaware 19805, US |
Phone | (302) 644-5427 |
Technologies |
JavaScript,
HTML,
PHP
+40 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biopharma, Healthcare, Biotechnology, Health Care, Science and Engineering, Pharmaceutical, Therapeutics |
Keywords | Precision Oncology, Oncology, Cancer Treatment |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Prelude Therapeutics employee's phone or email?
The Prelude Therapeutics annual revenue was $40 million in 2024.
Kris Vaddi is the Chief Executive Officer and Founder of Prelude Therapeutics.
146 people are employed at Prelude Therapeutics.
Prelude Therapeutics is based in Wilmington, Delaware.
The NAICS codes for Prelude Therapeutics are [32, 3254, 32541, 325].
The SIC codes for Prelude Therapeutics are [283, 28].